These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 4392046)

  • 1. [Beta-blocking compounds and production of ATP in leukocytes of hyperthyroid subjects].
    Jemelin M; Scazziga B; Frei J
    Schweiz Med Wochenschr; 1970 Mar; 100(12):543-4. PubMed ID: 4392046
    [No Abstract]   [Full Text] [Related]  

  • 2. Production of ATP in leukocyte mitochondria from hyperthyroid patients before and after treatment with a beta-adrenergic blocker and antithyroid drugs.
    Jemelin M; Frei J; Scazziga B
    Acta Endocrinol (Copenh); 1971 Apr; 66(4):606-10. PubMed ID: 4396496
    [No Abstract]   [Full Text] [Related]  

  • 3. Abnormalities of oxidative phosphorylation due to excess of deficiency of thyroid hormones.
    Popovici D; Mihai N; Urbanavicius V
    Endocrinologie; 1980; 18(3):143-7. PubMed ID: 7433860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulatory effects of oxprenolol, a new beta-adrenergic blocking agent.
    Reale A; Motolese M; Imhof P
    Int Z Klin Pharmakol Ther Toxikol; 1970 Jul; 3(3):288-93. PubMed ID: 4394124
    [No Abstract]   [Full Text] [Related]  

  • 5. [The influence of inorganic iodine on the oxidative phosphorylation process in the mitochondria of the brain and kidneys in normal and hyperthyroid rabbits].
    Rachev RR
    Biull Eksp Biol Med; 1966 Jan; 61(1):53-5. PubMed ID: 6004522
    [No Abstract]   [Full Text] [Related]  

  • 6. [On the effect of methothyrin on the process of oxidative phosphorylation in the myocardial mitochondria of hyperthyroid animals].
    Rachev RR
    Probl Endokrinol Gormonoter; 1966; 12(2):105-11. PubMed ID: 4177059
    [No Abstract]   [Full Text] [Related]  

  • 7. Acute circulatory effects of a beta adrenergic blocking agent (LB 46) in patients with sympathetic overstimulation.
    Dufour R; Scazziga B; Schelling JL
    Int Z Klin Pharmakol Ther Toxikol; 1970 Dec; 4(1):145-7. PubMed ID: 4395480
    [No Abstract]   [Full Text] [Related]  

  • 8. [The rôle of catecholamines in the clinical manifestations of the hyper- and hypothyroidism syndromes].
    Perrault M; Klotz B; Robillard M
    Sem Hop; 1968 Jun; 44(30):2013-25. PubMed ID: 4300528
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacological properties of a new beta-receptor blocking agent.
    Clark B; Saameli K
    Triangle; 1970; 9(8):300-8. PubMed ID: 4397310
    [No Abstract]   [Full Text] [Related]  

  • 10. [Use of adrenergic beta blockaders in thyrotoxicosis and hypothyroidism].
    Feldstein CA; Duhart JE; Henry EC; Degrossi OJ
    Prensa Med Argent; 1970 May; 57(9):454-8. PubMed ID: 4397115
    [No Abstract]   [Full Text] [Related]  

  • 11. The effect of LB-46, a new beta adrenergic blocking agent, on pulse and blood pressure at rest and after exercise in healthy volunteers.
    Mehta AB; Cooverji ND; Agrawal AB; Shah AC; Patnekar PN; Vora DD
    J Assoc Physicians India; 1971 Nov; 19(11):765-70. PubMed ID: 4399862
    [No Abstract]   [Full Text] [Related]  

  • 12. Some haemodynamic effects of LB 46 (Visken).
    Smyth AJ; Watson O; Peel JS; Turner AS
    N Z Med J; 1970 Oct; 72(461):246-7. PubMed ID: 4395124
    [No Abstract]   [Full Text] [Related]  

  • 13. [Beta blocking agents in thyroid diseases (author's transl)].
    Laroche C; Cremer GA; Boissonnas A; Detilleux M
    Therapie; 1980; 35(1):45-60. PubMed ID: 6106302
    [No Abstract]   [Full Text] [Related]  

  • 14. [Oxidation of palmityl carnitine in mitochondria of rat heart and liver tissue under conditions of thyroid pathology].
    Turakulov IaKh; Saatov TS; Rakhimdzhanova MT; Ismailkhodzhaeva G
    Vopr Med Khim; 1981; 27(2):197-200. PubMed ID: 7281559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical study on the action of a beta blocking agent (LB 46) on some manifestations of hyperthyroidism and hypothyroidism].
    Bricaire H; Pandos
    Presse Med (1893); 1971 Nov; 79(51):2301-4. PubMed ID: 5129469
    [No Abstract]   [Full Text] [Related]  

  • 16. Energetic leukocyte metabolism. II. Incorporation of phosphate-P32 into leukocytes and identification of P-32 labelled compounds by high voltage electrophoresis.
    Aleyassine H; Frei J
    Enzymol Biol Clin (Basel); 1966; 7(1):89-97. PubMed ID: 5296866
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparison of immediate haemodynamic effects of three beta-adrenergic blocking agents.
    Rivier JL; Nissiotis E; Jaeger M
    Postgrad Med J; 1970 Nov; ():Suppl:44-9. PubMed ID: 4395457
    [No Abstract]   [Full Text] [Related]  

  • 18. Drugs for hypothyroidism and hyperthyroidism.
    Medical Letter, Inc
    Treat Guidel Med Lett; 2006 Apr; 4(44):17-24. PubMed ID: 16554701
    [No Abstract]   [Full Text] [Related]  

  • 19. [Review of literature and experimental contribution on KO 592, a drug with beta-adrenolytic activity. I].
    Marmo E; Caputi AP; Saini RK
    Clin Ter; 1972 Jul; 62(1):11-51. PubMed ID: 4403671
    [No Abstract]   [Full Text] [Related]  

  • 20. [The effect of ascorbic acid on oxidative phosphorylation in cerebral mitochondria in thyrotoxicosis].
    Pokotilenko GM; Poliachenko LIu
    Vrach Delo; 1968 Mar; 3():77-9. PubMed ID: 5663879
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.